FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted on July 23–24, 2026 to recommend six peptides for inclusion on the Section 503A Bulk Drug Substances List, overriding FDA staff recommendations on every single nomination. The six peptides are BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — several of which are widely used in biohacking and peptide telehealth communities but currently lack a formal compounding pathway under federal law.
The votes represent the first formal advisory recommendation to add these substances to the legal compounding route for traditional pharmacies. However, the PCAC’s recommendation is non-binding. As of September 17, 2026, none of the six peptides have been added to the official 503A Bulks List codified at 21 CFR 216.23. Formal rulemaking is still required before compounding pharmacies could lawfully use these bulk drug substances under Section 503A.
The development carries significant weight for compounding pharmacies, peptide telehealth providers, and consumers, but it does not authorize compounding today. Legal experts estimate the rulemaking process could extend into 2027–2028.
What happened
The PCAC considered seven peptide nominations across its July 23–24 meeting. The committee voted to recommend six for the 503A Bulks List, each tied to a specific clinical use cited in the nomination:
- BPC-157 — recommended 8–6 for ulcerative colitis
- TB-500 — recommended 8–6 for wound healing
- KPV — recommended 8–6 for wound healing and inflammation
- MOTS-c — recommended 7–5 for obesity and osteoporosis
- Semax — recommended 8–5 for cerebral ischemia and migraine
- Epitalon — recommended 7–4 for insomnia
Emideltide (DSIP) was not recommended, failing on a 6–7 vote.
Notably, the committee’s recommendations diverged from FDA staff positions on all six approved peptides. The PCAC is an advisory body, and its votes do not by themselves change the regulatory status of any substance. Adding a bulk drug substance to the 503A list requires formal federal rulemaking, including notice-and-comment procedures.
According to updated tracking published September 17, 2026, the 503A Bulks List remains unchanged. None of the six recommended peptides have been added.
Why it matters
The PCAC vote marks a notable moment in the ongoing debate over peptide compounding. Substances like BPC-157 and TB-500 have generated substantial consumer interest and are sold through channels outside FDA-approved pathways, but they have never had a recognized pathway for lawful compounding under Section 503A. The committee’s recommendation — made against FDA staff advice — reflects a divergence of views among advisory members and agency staff, but it is not itself a scientific or regulatory finding of safety or efficacy; any such determination would depend on the formal rulemaking process.
The gap between an advisory vote and a final rule is significant. Consumers and compounders should understand that the PCAC recommendation does not confer legal compounding status. Until FDA completes rulemaking and amends 21 CFR 216.23, these substances remain outside the 503A framework.
At the same time, FDA has been pursuing what observers describe as a dual-track approach. While the 503A bulks list process moves forward, the agency has simultaneously issued warning letters to five peptide vendors for unapproved peptide sales. This enforcement activity underscores that the current regulatory status of these peptides outside formal pathways remains restricted.
What to watch next
- Rulemaking timeline: Watch for FDA’s formal rulemaking proceedings on the six recommended peptides. Legal observers estimate the process could take until 2027–2028.
- Second PCAC meeting: A follow-up PCAC meeting is expected before February 2027 to consider additional peptide nominations, including LL-37, GHK-Cu, Dihexa acetate, Melanotan II, Mechano Growth Factor, and Pegylated MGF.
- Enforcement actions: FDA’s warning letters to peptide vendors suggest continued enforcement against unauthorized sales while the 503A process unfolds.
- Emideltide (DSIP): The committee’s decision not to recommend DSIP leaves its compounding status unchanged for now.
Sources
- Yoon Hang Kim / FDA PCAC — FDA Peptide Compounding Update
- Mondaq / FDA — FDA Balances Peptide Policy with Enforcement Against Unlawful Peptide Sellers
Industry information only. Not medical or legal advice.
